The University of Louisiana at Monroe (ULM) received a $137,750 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to investigate the use of synthetic somatostatin analogs (SSAs) to protect against endothelial barrier dysfunction (EBD). The research aims to examine the role of specific SSAs (lanreotide, octreotide, and pasireotide) in mitigating EBD induced by lipopolysaccharide (LPS) and interferon-gamma (IFNγ) in human lung microvascular endothelial cells. The project will also explore the involvement of the ATF6 transcription factor in the protective effects of SSAs against EBD, and test the effects of SSAs in a murine model of LPS-induced acute lung injury. This research seeks to identify a potential new therapeutic application for FDA-approved SSAs in disorders related to EBD, such as acute respiratory distress syndrome (ARDS).
Generated 2/25/25, 3:29 AM